Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2019 | Using the urinary microbiome to predict BCG therapy responses in bladder cancer patients.

Bacillus Calmette-Guérin (BCG) immunotherapy is the standard care for patients with non-muscle invasive bladder cancer (NMIBC). However, up to fifty percent of patients have reoccurrence of tumours or further progression to invasive disease within five years. Randy Sweis, MD, of the University of Chicago Medical Center, Chicago, IL, speaks at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, and details how by examining the urine microbiome of patients and specifically biomarkers within the urine microbiome, one can begin to predict responses to the BCG therapy, as well as potentially predicting further immune responses to the treatment and more generally, bladder cancer.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.